Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

NCT01127633 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1457

Enrollment

INDUSTRY

Sponsor class

Stopped Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.

Conditions

Alzheimer's Disease

Interventions

DRUG: Solanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company